Prospective clinical efficacy study of latanoprostene bunod 0.024%
DOI:
https://doi.org/10.70313/2718.7446.v16.n03.240Keywords:
latanoprostene bunod, Vyzulta, latanoprost, ocular surface, glaucomaAbstract
Objective: To evaluate the hypotensive efficacy and perception of patients treated with latanoprostene bunod 0.024%.
Methods: A single-center clinical study of a case series was performed, including patients who were on previous treatment with latanoprost 0.005, who after a washout period were started on latanoprostene bunod. Intraocular pressure, before the change of treatment and at 3 months, and patients’ opinion, explored through questions related to the perceived differences between both treatments, were evaluated. Best corrected visual acuity and the biomicroscopic aspect of the ocular surface assessed by fluorescein staining (Oxford scale) were also measured.
Results: A total of 36 patients (72 eyes) performed the study. IOP was 13.4 ± 2.1 (9-18) at baseline and at 3 months 13.1 ± 1.7 (9-16), a difference that was not statistically significant (p=0.63). The score obtained with the Oxford scale was 0.6 ± 0.7 (0-3) at baseline, 0.5 ± 0.8 (0-2) at 1 month and at 3 months decreased to 0.2 ± 0.8 (0-2), with a statistically significant difference (p=0.01). Preference of patients who were previously with latanoprost and subsequently used latanoprostene bunod: 41.7%; latanoprost 22.2%; indistinct: 36.1%.
Conclusion: Latanoprostene bunod treatment was at least as effective as latanoprost, but resulted in improved the ocular surface. This could be one reason why almost twice as many patients preferred latanoprostene bunod after three months of treatment.
Downloads
References
Kaufman PL. Latanoprostene bunod ophthalmic solution 0.024% for IOP lowering in glaucoma and ocular hypertension. Expert Opin Pharmacother 2017; 18: 433-444.
Weinreb RN, Scassellati Sforzolini B, Vittitow J, Liebmann J. Latanoprostene bunod 0.024% versus timolol maleate 0.5% in subjects with open-angle glaucoma or ocular hypertension: the APOLLO Study. Ophthalmology 2016; 123: 965-973.
Medeiros FA, Martin KR, Peace J et al. Comparison of latanoprostene bunod 0.024% and timolol maleate 0.5% in open-angle glaucoma or ocular hypertension: the LUNAR Study. Am J Ophthalmol 2016; 168: 250-259.
Weinreb RN, Liebmann JM, Martin KR et al. Latanoprostene bunod 0.024% in subjects with open-angle glaucoma or ocular hypertension: pooled phase 3 study findings. J Glaucoma 2018; 27: 7-15.
Lo TC, Chen YY, Hung MC, Chou P. Latanoprostene bunod 0.024% in the treatment of open-angle glaucoma and ocular hypertension: a meta-analysis. J Clin Med 2022; 11: 4325.
Harasymowycz P, Royer C, Cui AX et al. Short-term efficacy of latanoprostene bunod for the treatment of open-angle glaucoma and ocular hypertension: a systematic literature review and a network meta-analysis. Br J Ophthalmol 2022; 106: 640-647.
Robin A, Grover DS. Compliance and adherence in glaucoma management. Indian J Ophthalmol 2011; 59 (Suppl. 1): S93-S96.
Zaharia AC, Dumitrescu OM, Radu M, Rogoz RE. Adherence to therapy in glaucoma treatment-a review. J Pers Med 2022; 12: 514.
Fogagnolo P, Torregrossa G, Tranchina L et al. Tear film osmolarity, ocular surface disease and glaucoma: a review. Curr Med Chem 2019; 26: 4241-4252.
Wallace S, Edmond J. In support of ophthalmology-specific patient-reported outcome measures. Ophthalmology 2019; 126: 690-691.
Vandenbroeck S, De Geest S, Zeyen T et al. Patient-reported outcomes (PRO’s) in glaucoma: a systematic review. Eye (Lond) 2011; 25: 555-577.
Villacorta-Gassmann P. Cuestionarios: herramientas de estudio en oftalmología. Oftalmol Clin Exp 2023; 16: e6-e14.
Bron AJ, Evans VE, Smith JA. Grading of corneal and conjunctival staining in the context of other dry eye tests. Cornea 2003; 22: 640-650.
Weinreb RN, Ong T, VOYAGER study group et al. A randomised, controlled comparison of latanoprostene bunod and latanoprost 0.005% in the treatment of ocular hypertension and open angle glaucoma: the VOYAGER study. Br J Ophthalmol 2015; 99: 738-745.
Wang Y, Liao Y, Nie X. Comparative evaluation of latanoprostene bunod, timolol maleate, and latanoprost ophthalmic solutions to assess their safety and efficacy in lowering intraocular pressure for the management of open-angle glaucoma. Clinics (São Paulo) 2020; 75: e1874.
Fenwick EK, Man RE, Aung T et al. Beyond intraocular pressure: optimizing patient-reported outcomes in glaucoma. Prog Retin Eye Res 2020; 76: 100801.
Craig JP, Nichols KK, Akpek EK et al. TFOS DEWS II definition and classification report. Ocul Surf 2017; 15: 276-283.
Arntz A, Ibañez C, Covarrubias T. Unexplained ocular and visual symptoms: the need for a psychosomatic approach in ophthalmology. Arch Soc Esp Oftalmol (Engl Ed) 2019; 94: 575-578.
Asiedu K, Dzasimatu SK, Kyei S. Impact of dry eye on psychosomatic symptoms and quality of life in a healthy youthful clinical sample. Eye Contact Lens 2018; 44 Suppl 2: S404-S409.
Sabel BA, Wang J, Cárdenas-Morales L et al. Mental stress as consequence and cause of vision loss: the dawn of psychosomatic ophthalmology for preventive and personalized medicine. EPMA J 2018; 9: 133-160.
Emmerich GM. Psychosomatic aspects in preparation and follow-up in glaucoma surgery and their special impact on patients. Klin Monbl Augenheilkd 2021; 238: 146-152.
Tau J, Passerini MS, Del Papa M et al. A novel ophthalmic latanoprost 0.005% nanoemulsion: a cytotoxicity study. Graefes Arch Clin Exp Ophthalmol 2022; 260: 1941-1946.
Casiraghi JF, Grigera D, Peyret JA et al. Efficacy and tolerability of a new latanoprost 0.005% BAK-free nanoemulsion: a nonrandomized open-label trial. Re:GEN Open 2021; 1: 110-116. Disponible en: https://www.liebertpub.com/doi/10.1089/regen.2021.0018
Tummanapalli SS, Kuppusamy R, Yeo JH et al. The role of nitric oxide in ocular surface physiology and pathophysiology. Ocul Surf 2021; 21: 37-51.
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Consejo Argentino de Oftalmología
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Con esta licencia no se permite un uso comercial de la obra original, ni la generación de obras derivadas. Las licencias Creative Commons permiten a los autores compartir y liberar sus obras en forma legal y segura.
How to Cite
